ERBB2 and breast carcinoma: Our findings highlight the clinical, biological, and metabolic heterogeneity of HER2+ breast cancer, which may facilitate to select HER2+ EBC patients likely to benefit from [18F]FDG-PET imaging as a tool to guide therapy.